Neoadjuvant Chemotherapy as Standard-of-Care for Muscle-Invasive Urothelial Carcinoma
Srikala Sridhar, MD, MSc, FRCPC, explains the importance of neoadjuvant cisplatin-based chemotherapy and why bladder-sparing treatments should be considered for all patient populations.
EP: 1.Incidence and Risk Factors for Urothelial Carcinoma
Now Viewing
EP: 2.Neoadjuvant Chemotherapy as Standard-of-Care for Muscle-Invasive Urothelial Carcinoma
EP: 3.Neoadjuvant Chemotherapy in Urothelial Carcinoma: The CHECKMATE-274 Trial
EP: 4.Neoadjuvant Chemotherapy in Urothelial Carcinoma: The IMvigor010 Study
EP: 5.Treatment Options for Frontline Metastatic Urothelial Carcinoma
EP: 6.Outcomes of the JAVELIN Bladder 100 Trial
EP: 7.Metastatic Urothelial Carcinoma Treatment after Disease Progression on Avelumab
EP: 8.Key Trial Data in Urothelial Carcinoma Treatment from ESMO 2022
Related Videos
Related Content
